<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Sangamo Biosciences Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/sangamo-biosciences-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGMO) Sangamo Biosciences &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/10/16/sgmo-sangamo-biosciences-bull-of-the-day/17742</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sgmo-sangamo-biosciences-bull-of-the-day/17742#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:18:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17742</guid>
		<description><![CDATA[Sangamo Biosciences, Inc. (SGMO) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases. We are optimistic about this novel technology. SB-509 has shown some positive results for the treatment of moderate to severe DN. We are also optimistic about other clinical programs. Further, we are impressed by the company&#8217;s strategy to monetize this ZFP technology. We maintain our Outperform rating on shares of Sangamo based on the platform technology and the progress the company has made for both its clinical and preclinical programs. Our target price is $10.00. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sgmo-sangamo-biosciences-bull-of-the-day/17742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

